Quick adme quote
The ADMET Toolkit: Impact on Compound Design and Optimization
Abstract:
This webinar delves into the challenges and innovative solutions for predicting human pharmacokinetics and exposure, essential for clinical success. Learn how early identification of liabilities and a focus on exposure can significantly improve compound selection and reduce attrition rates, with the ADMET toolkit.
Learning objectives:
- What is ADMET and why is it critical to drug discovery?
- Why is (predicted) human PK and exposure so key to success?
- What are the key ADMET challenges?
- How to design a fit-for-purpose screening cascade?
- How to anticipate/identify ADMET challenges and develop adapted solutions?
Dr Rob Riley | ADME & DMPK Expert | Independant
Dr. Riley, an expert with over 30 years of experience, explores the critical role of ADMET/DMPK in modern drug discovery. He has over 30 years experience in Biopharmaceutical Research & Development in the major therapeutic areas. A pharmacologist by training with a keen eye for compound properties and quality, Rob oversaw the delivery of many meaningful medicines, including Kengreal and Brilinta, while in pharma (Fisons, Astra, Astrazeneca; ~25 years) as Head of DMPK and Chemistry. He recently served as Head of Worldwide DMPK at Evotec and Head of Cyprotex
Dr. Tom Pesnot | Drug Discovery Services Director | Concept Life Sciences
Tom joined Concept Life Sciences in 2017. He has over 15 years’ experience of leading drug discovery programmes in the academic, biotech, and CRO sectors, and contributed to the development of multiple clinical candidates and marketed drugs. His scientific expertise spans a wide range of therapeutic areas (oncology, immuno-oncology, fibrosis and neurosciences) and target classes (kinases, enzymes, GPCRs, ion channels) at all stages of the drug discovery process. A Fellow of the Royal Society of Chemistry, Thomas has authored over 35 publications, reviews, and patents in the field of drug discovery, synthetic chemistry, and enzymology.